Clinical trials in Augsburg – page 5

300 clinical trials in Augsburg, Germany across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Augsburg at a glance

300

clinical trials

Research sites3

Quick filters

300 trials in Augsburg

Open in trial search

Gastrooesophageal cancer+1

Recruiting

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

A study comparing trifluridine, tipiracil, and fruquintinib versus trifluridine and tipiracil alone for patients with metastatic stomach or esophageal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fruquintinib
Sponsor:Fondation Franc.Cancerologie Digestive

Contact Research Centre

Ischaemic stroke

Recruiting

A study testing tenecteplase given directly into the artery after blood clot removal in patients with acute ischemic stroke in the front part of the brain

Registered drug

A study testing tenecteplase given directly into the artery after blood clot removal in patients with acute ischemic stroke in the front part of the brain

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Pfizer Inc.

Contact Research Centre

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Small cell lung cancer recurrent

Recruiting

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:GSK5764227
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Busulfan
Sponsor:Medizinische Hochschule Hannover

Contact Research Centre

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Breast cancer+1

Recruiting

Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo

Study of typology-based coaching and education to help patients with early hormone-positive HER2-negative breast cancer manage their treatment with ribociclib

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ribociclib
Sponsor:Institut fuer Frauengesundheit GmbH

Contact Research Centre

Li-Fraumeni syndrome

Recruiting

Study of metformin for cancer prevention in adolescents and adults with Li-Fraumeni syndrome

Registered drugNo placebo

Study of metformin for cancer prevention in adolescents and adults with Li-Fraumeni syndrome

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Metformin
Sponsor:Medizinische Hochschule Hannover

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Ibuzatrelvir
Sponsor:Pfizer Inc.

Contact Research Centre

Colitis ulcerative

Recruiting

Comparing mirikizumab versus azathioprine with glucocorticoids in newly diagnosed patients with moderate-to-severe ulcerative colitis

Registered drugNo placebo

Comparing mirikizumab versus azathioprine with glucocorticoids in newly diagnosed patients with moderate-to-severe ulcerative colitis

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Azathioprine
Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

Registered drugNo placebo

Study of Darolutamide and Testosterone for Patients with Advanced Prostate Cancer Resistant to Standard Hormone Therapy

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Universitaet Muenster

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Augsburg

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on breast cancer, lung cancer, and lymphoma treatments. Studies evaluating novel therapeutic approaches including targeted therapies and immunotherapy combinations.

HR-positive breast cancer treatment evaluation
Advanced non-small cell lung cancer therapies
Lymphoma and leukemia interventions

Several trials are investigating combination therapies to improve patient outcomes in various cancer types.

02 Dermatology Studies

Comprehensive research into plaque psoriasis and atopic dermatitis, with multiple trials testing new therapeutic agents and preventive approaches.

Moderate to severe psoriasis treatments
Preventive interventions for atopic dermatitis
Long-term safety assessments

Focus on both treatment and prevention strategies for chronic skin conditions.

03 Gastrointestinal Research

Innovative studies addressing ulcerative colitis and gastroparesis, testing novel therapeutic approaches and treatment combinations.

Ulcerative colitis treatment optimization
Gastroparesis symptom management
Biliary tract cancer therapies

Trials aim to improve quality of life and treatment outcomes for patients with chronic digestive conditions.

Back to Germany All countries